Basket cover image
15 handpicked stocks

Thrill & Excitement Fund

Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juin 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

SPCE

Virgin Galactic Holdings Inc

SPCE

Current price

$2.97

As a key player in the commercial space tourism sector, this company epitomizes high-risk investment in a frontier industry.

DKNG

DraftKings

DKNG

Current price

$45.02

This company is a dominant force in the high-growth, rapidly expanding market of online sports betting and daily fantasy sports.

RCKT

Rocket Pharmaceuticals Inc

RCKT

Current price

$2.72

This clinical-stage biotechnology company focuses on gene therapies for rare diseases, representing a high-stakes bet on medical breakthroughs.

About This Group of Stocks

1

Our Expert Thinking

This portfolio taps into markets with extraordinary growth potential. We've targeted companies operating at innovation's frontiers — from space tourism pioneers to biotech firms developing breakthrough therapies and digital platforms revolutionizing online gaming. The big idea? Capturing potential exponential returns from disruptive technologies and emerging market leaders.

2

What You Need to Know

These investments come with significant volatility and risk, balanced by potential for outsized rewards. Many companies are pre-profitability, operating in rapidly evolving sectors like commercial space travel, gene therapy, and online betting. Consider these as high-octane additions to a well-diversified portfolio, not your core investments.

3

Why These Stocks

Each company was selected based on its disruptive potential rather than current financial performance. We've focused on operations with compelling concepts targeting massive growth markets. Current catalysts include the rapid expansion of legalized online sports betting and significant advancements in clinical-stage biopharmaceuticals.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+565.64%

Group Performance Snapshot

565.64%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 565.64% over the next year.

12 of 14

Stocks Rated Buy by Analysts

12 of 14 assets in this group are rated Buy by professional analysts.

1.1%

Group Growth

This group averaged a 1.1% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

Reach for the Stars

From actual space tourism to groundbreaking medical therapies, these companies aren't just growing businesses – they're creating entirely new industries from scratch.

🎲

Bet on the Future

The rapid expansion of legal online betting markets is creating billion-dollar opportunities overnight. These companies are positioning to capture massive new revenue streams as regulations evolve.

💉

Medical Breakthroughs Ahead

Several biotech picks are approaching critical clinical milestones that could completely transform their market value. One positive announcement could change everything.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.